Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29681462 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRALOX15LMNA | |
| SCHEMBL16247844 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRALOX15 | |
| SCHEMBL8055181 | 0.73 | TDP1 (0.35) | ALDH1A1TSHRLMNAMEN1MAPT | |
| SCHEMBL17222720 | 0.71 | ALDH1A1 (0.39) | ALDH1A1TSHRALOX15CYP1A2 | |
| SCHEMBL218726 | 0.69 | ALDH1A1 (0.54) | ALDH1A1TSHRALOX15CYP1A2 | |
| SCHEMBL31218226 | 0.68 | HTT (0.44) | ALDH1A1TSHRMEN1MAPTKMT2A | |
| SCHEMBL22075893 | 0.67 | ALDH1A1 (0.35) | ALDH1A1TSHRALOX15LMNAMEN1 | |
| SCHEMBL4446227 | 0.67 | ALDH1A1 (0.41) | ALDH1A1TSHRALOX15LMNAMEN1 | |
| SCHEMBL1323446 | 0.67 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15CYP1A2 | |
| SCHEMBL49187 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396191-B1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250129092-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-04-24 | — | — | US | disclosed |
| US-20240317775-A1 | H4 Antagonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| CN-118496204-A | Deuterated pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4396191-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2024-07-10 | — | — | EP | disclosed |
| CN-118076613-A | Compounds useful for modulating AhR signaling | 捷豹治疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023033740-A9 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2023-12-28 | — | — | WO | disclosed |
| EP-4259637-A1 | H4 ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023033740-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2023-03-09 | — | — | WO | disclosed |
| US-20140065136-A1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014033196-A1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033196-A1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| US-20140065136-A1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2651951-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317775-A1 | H4 Antagonist Compounds | HRH4, HRH3, H1-4 | ALDH1A1 2366/4885TSHR 111/4885ALOX15 2243/4885 |
| US-20250129092-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | AHR, ARNT, AIPL1 | ALDH1A1 516/4885TSHR 1129/4885ALOX15 108/4885 |
| US-20140065136-A1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 1834/4885TSHR 2868/4885ALOX15 542/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | ALDH1A1 4455/4885TSHR 3238/4885ALOX15 1690/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | ALDH1A1 4070/4885TSHR 1145/4885ALOX15 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.